Today: 4 June 2026

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Fluence Energy (FLNC) Stock Today: Downgrades Hit High-Flying Battery Storage Play – Latest News, Price Targets and Forecasts

Fluence Energy (FLNC) Stock Today: Downgrades Hit High-Flying Battery Storage Play – Latest News, Price Targets and Forecasts

Fluence Energy shares fell about 7–8% intraday on December 8 after Mizuho and Johnson Rice downgraded the stock, citing valuation and execution risks. The drop followed a sharp rally, with the stock still up over 30% year-to-date and trading near $22. The company reported $2.3 billion in fiscal 2025 revenue and announced a new UK battery project milestone. Wall Street consensus targets imply significant downside from current levels.
8 December 2025
··
Marvell Technology (MRVL) Stock Tumbles on Amazon and Microsoft Fears as AI Growth Story Gets Re‑Priced

Marvell Technology (MRVL) Stock Tumbles on Amazon and Microsoft Fears as AI Growth Story Gets Re‑Priced

Marvell Technology shares fell as much as 10% intraday on December 8 after Benchmark downgraded the stock, citing likely losses of Amazon’s Trainium 3 and 4 chip designs and concerns Microsoft could shift custom silicon work to Broadcom. The stock closed about 7% lower at $92.61. Zacks, meanwhile, upgraded Marvell to “Strong Buy” the same day, citing rising earnings estimates.
8 December 2025
···
Warby Parker (WRBY) Stock Soars on Google AI Glasses Timeline: Price Action, Earnings and 2026 Forecasts as of December 8, 2025

Warby Parker (WRBY) Stock Soars on Google AI Glasses Timeline: Price Action, Earnings and 2026 Forecasts as of December 8, 2025

Warby Parker shares surged nearly 15% to $21.51 on December 8 after new disclosures confirmed a 2026 launch of AI-powered smart glasses with Google under the Android XR platform. Trading volume spiked above average, pushing the stock about 58% above its 52-week low. Google has committed up to $150 million to the partnership. Warby Parker’s year-to-date stock performance remains down 26% despite the rally.
8 December 2025
··
Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals shares jumped 14–15% intraday on 8 December 2025, reaching a 52-week high near $69 after dosing the first subjects in its Alzheimer’s trial ARO-MAPT. The stock has returned about 270% year-to-date, with a market cap around $9–9.6 billion. The Phase 1/2a trial targets tau protein using Arrowhead’s RNAi platform. Liquidity ratios stand near 4.8, with beta between 1.3 and 1.5.
8 December 2025
·
Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics shares jumped about 20% to $21.70 intraday on December 8, 2025, after new Phase 1 data for its BTK degrader bexobrutideg (NX-5948) in blood cancers was presented at the ASH Annual Meeting. The company reported an 83% response rate in relapsed/refractory CLL/SLL patients and scheduled a webcast for the evening. Volume was well above normal, with shares trading near a 52-week high.
8 December 2025
··
Carvana (CVNA) Soars on S&P 500 Inclusion: Latest News, Stock Forecast and Analysis as of December 8, 2025

Carvana (CVNA) Soars on S&P 500 Inclusion: Latest News, Stock Forecast and Analysis as of December 8, 2025

Carvana shares jumped about 14% to $454 on December 8 after S&P Dow Jones Indices said the company will join the S&P 500 on December 22. The stock is up over 115% in 2025 and has surged more than 8,000% since 2022 lows. Carvana’s market value now stands near $87 billion, surpassing Ford and GM. Index funds are expected to buy shares ahead of the inclusion.
8 December 2025
··
Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics shares jumped nearly 50% Monday, closing near $96 after hitting an intraday high above $100, following strong Phase 1b results for its oral STAT6 degrader KT‑621 in atopic dermatitis. The trial showed about 98% median STAT6 degradation in blood and 94% in skin lesions. Trading volume was far above normal. Stifel raised its price target as the stock marked a new 52-week high.
8 December 2025
··
Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough – What the New Data and Wall Street Forecasts Signal

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough – What the New Data and Wall Street Forecasts Signal

Wave Life Sciences shares soared as much as 140% Monday after reporting positive interim Phase 1 data for its obesity drug WVE-007. The stock hit $17–18 intraday on record volume topping 100 million shares, up from Friday’s $7.49 close. The trial showed a 9.4% drop in visceral fat and a 3.2% gain in lean mass at three months. Wave’s market value rose to about $2.5–3.0 billion.
8 December 2025
·
Confluent (CFLT) Soars on IBM’s $11 Billion Takeover: Deal Terms, Stock Outlook and Analyst Forecasts After December 8, 2025 Rally

Confluent (CFLT) Soars on IBM’s $11 Billion Takeover: Deal Terms, Stock Outlook and Analyst Forecasts After December 8, 2025 Rally

IBM will acquire Confluent for $31 per share in cash, valuing the company at about $11 billion. Confluent stock jumped nearly 29% on December 8, trading close to the buyout price after the deal was announced. Both boards approved the agreement, with major shareholders backing the transaction. Closing is expected by mid-2026, pending shareholder and regulatory approval.
8 December 2025
···
Banco Bradesco (BBD) Stock on December 8, 2025: Is the Post‑Earnings Sell‑Off a Buying Opportunity?

Banco Bradesco (BBD) Stock on December 8, 2025: Is the Post‑Earnings Sell‑Off a Buying Opportunity?

Banco Bradesco ADRs traded near $3.35 on December 8, 2025, recovering slightly after a 9% drop on December 5. Q3 net income rose 18.8% year-on-year to R$6.2 billion, but earnings per share missed estimates, triggering the selloff. Hedge funds cut stakes in Q2 while Fisher Asset Management raised its position. Analysts maintain a consensus “Buy” rating with 12-month targets between $2.40 and $3.72.
8 December 2025
··
Spirit AeroSystems (SPR) Stock on December 8, 2025: Boeing Takeover, NYSE Delisting and What Shareholders Get

Spirit AeroSystems (SPR) Stock on December 8, 2025: Boeing Takeover, NYSE Delisting and What Shareholders Get

Boeing completed its acquisition of Spirit AeroSystems on December 8, 2025, halting SPR trading and starting the NYSE delisting process. Each Spirit share will convert into 0.1955 Boeing shares. The deal values Spirit at about $4.7 billion in equity, or $8.3 billion including debt. Airbus will take over key Spirit sites and receive $439 million in compensation.
8 December 2025
···
Rivian Stock on December 8, 2025: Downgrade, Recall and R2 Hopes – What RIVN Investors Need to Know

Rivian Stock on December 8, 2025: Downgrade, Recall and R2 Hopes – What RIVN Investors Need to Know

Rivian shares fell 3–5% Monday to about $17.30 after Morgan Stanley downgraded the stock to Underweight and kept a $12 target. The move follows a recall of nearly 35,000 delivery vans and concerns over Rivian’s upcoming R2 SUV amid slowing EV demand. The stock remains up about 38–45% over the past year but is still down roughly 90% from its 2021 peak.
8 December 2025
·
UiPath (PATH) Stock Soars After First GAAP Profit: Can the AI Automation Rally Last? – December 8, 2025

UiPath (PATH) Stock Soars After First GAAP Profit: Can the AI Automation Rally Last? – December 8, 2025

UiPath shares hit new 52-week highs, closing at $19.12 on Dec. 8, 2025, after posting its first GAAP-profitable quarter and raising guidance. The stock has surged about 30% in the past month and over 50% in the last year, outpacing the S&P 500. Trading volume neared 19 million shares. Most analysts’ price targets remain below current levels.
8 December 2025
··
Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics shares surged 101% to $69.46 on December 8 after reporting positive Phase 2b data for aleniglipron, its oral GLP-1 agonist for obesity. Patients on 120 mg lost 12.1% of body weight at 36 weeks versus 0.8% for placebo. The company held $799 million in cash as of September 30.
8 December 2025
···
Bitcoin Nears $92K as Fed Rate-Cut Bets and XRP ETF Boom Lift Crypto – BTC, ETH, XRP and Solana Price Outlook for December 8, 2025

Bitcoin Nears $92K as Fed Rate-Cut Bets and XRP ETF Boom Lift Crypto – BTC, ETH, XRP and Solana Price Outlook for December 8, 2025

The total crypto market cap rose 2.2% to $3.2 trillion on Monday, December 8, 2025, as Bitcoin traded near $91,500 and Ethereum hovered around $3,130. Traders cited Federal Reserve rate-cut expectations and strong inflows into crypto ETFs. XRP held above $2.00 with U.S. spot ETFs nearing $1 billion AUM. Solana climbed to the mid-$130s amid continued ETF inflows.
8 December 2025
··
Opendoor Technologies (OPEN) Stock Today: Meme Rally, AI Pivot and 2026 Forecasts – December 8, 2025

Opendoor Technologies (OPEN) Stock Today: Meme Rally, AI Pivot and 2026 Forecasts – December 8, 2025

Opendoor shares closed at $7.15 on Dec. 5, up over 350% year-to-date from $1.60, despite continued losses and recent dilution. Q3 2025 revenue fell 33% to $915 million, with a net loss of $90 million. Wall Street’s 12-month price targets remain far below current levels, clustering between $1.70 and $2.90. Trading volume and search interest have surged amid meme stock activity.
8 December 2025
···
D-Wave Quantum (QBTS) Stock on December 8, 2025: Government Pivot, Qubits 2026 and Bubble Warnings Collide

D-Wave Quantum (QBTS) Stock on December 8, 2025: Government Pivot, Qubits 2026 and Bubble Warnings Collide

D-Wave Quantum (NYSE: QBTS) traded near $28 intraday on December 8, up over 3%, with its market cap approaching $9.7 billion despite ongoing losses and modest revenue. The stock has soared from a 52-week low of $2.50 to a high of $46.75 in 2025, posting extreme volatility and over 200% annual gains. D-Wave announced its Qubits 2026 user conference for January in Boca Raton, Florida.
8 December 2025
·
Canada’s F‑35 Crossroads: Quebec Maintenance Hub, Leaked Scorecard and a Last‑Minute Gripen Push

Canada’s F‑35 Crossroads: Quebec Maintenance Hub, Leaked Scorecard and a Last‑Minute Gripen Push

A leaked Department of National Defence chart shows the F-35 scored 95% against the Swedish Gripen’s 33% in Canada’s fighter jet competition. L3Harris MAS is pushing to make Mirabel, Quebec a major F-35 maintenance hub, with plans to service over 2,000 jets if Canada commits to the full F-35 order. The project could cost $200 million and affect 5,000 jobs. Prime Minister Mark Carney is nearing a final decision.
8 December 2025
··
1 … 506 507 508 509 510 … 587

Stock Market Today

  • Honeywell-Backed Quantinuum Raises $1.68 Billion in IPO
    June 4, 2026, 10:49 AM EDT. Quantinuum Inc., supported by Honeywell International, raised $1.68 billion in an upsized initial public offering (IPO) in the U.S. The quantum computing firm's strong capital raise reflects increasing investor interest in the emerging quantum technology sector, signaling confidence in its growth potential.

Latest articles

CXApp Stock Rockets After Tiny AI Firm Buys EngineRoom—The 75% Move Explained

CXApp Stock Rockets After Tiny AI Firm Buys EngineRoom—The 75% Move Explained

4 June 2026
CXApp shares soared about 75% in heavy Nasdaq trading after announcing its $4.6 million EngineRoom acquisition, expected to boost annualized revenue run-rate to over $12 million from $4 million; a June 3 filing also revealed CXApp issued 12.3 million shares to Avondale Capital, raising dilution concerns for investors.
Micron Drops as AI Memory Stocks Take a Hit

Micron Drops as AI Memory Stocks Take a Hit

4 June 2026
Micron Technology plunged 8.3% to $989.46 after a chip-sector selloff triggered by Broadcom’s revenue miss, but analysts say the memory-chip shortage could last years, with Morgan Stanley raising its target to $1,050; risks remain as Raymond James warns DRAM and NAND prices may peak mid-2026, and supply chain groups caution AI data centers are straining chip availability.
Quantinuum starts $1.68B Nasdaq debut, quantum stocks watch

Quantinuum starts $1.68B Nasdaq debut, quantum stocks watch

4 June 2026
Quantinuum raised $1.68 billion in a Nasdaq IPO at $60 per share—above its marketed range—giving investors access to a Honeywell-backed quantum computing pure-play as the U.S. government pledges $2 billion in quantum incentives, but the company posted a $192.6 million net loss on $30.9 million revenue in 2025 and remains reliant on a few customers, with Honeywell retaining about 48.1% ownership after the offering.
Solidion Shares Surge Following Space Battery Announcement

Solidion Shares Surge Following Space Battery Announcement

4 June 2026
Solidion shares soared 361% to $23.21 after unveiling a patented battery platform for satellites, AI data centers, and lunar infrastructure, despite no customer orders, limited cash of $38,887, minimal sales, a going-concern warning, and defaulted debt, making future financing and dilution key risks for investors.
UnitedHealth Shares Climb as Wall Street Sees Less Cost Pressure

UnitedHealth Shares Climb as Wall Street Sees Less Cost Pressure

4 June 2026
UnitedHealth Group surged 5.7% after Bank of America upgraded the stock to Buy and Morgan Stanley hiked its price target, as Wall Street cited signs of easing medical costs and a favorable second-quarter earnings setup, with shares trading near $398 and the board boosting the quarterly dividend to $2.32, even as a Massachusetts lawsuit poses ongoing risk.
Go toTop